Benchmarking of a Multi-biomarker Low-volume Panel for Alzheimer’s Disease and Related Dementia Research

Discover an informative webinar featuring leading researchers as they discuss advancements in biomarker discovery for Alzheimer’s disease (AD) and related dementias.

The expert speakers will present on the validation and application of a highly sensitive and low-volume multiplexed assay designed to detect key neurodegenerative disease biomarkers. They will explore how this platform enhances the measurement of critical Alzheimer’s biomarkers, such as pTau217, offering a minimally invasive and scalable approach for early diagnosis and disease monitoring in both sporadic and autosomal dominant AD.

They will follow with a discussion on large-scale plasma proteomics and its role in identifying disease-specific biomarkers across neurodegenerative diseases, including AD, Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). Her research highlights the power of plasma pTau217 as a predictive biomarker for amyloid pathology and the broader impact of proteomic profiling in precision medicine.

This webinar will showcase how the multiplexed assay is setting a new benchmark for biomarker research, enabling high-sensitivity, low-volume detection to transform Alzheimer’s and dementia diagnostics, research and clinical applications.

Speakers

Dr. Laura Ibáñez, PhD, Assistant Professor of Psychiatry, Washington University of Medicine

Dr. Laura Ibáñez received her doctoral degree in Biomedicine at the University of Barcelona in Spain. Her doctoral studies focused on the genetics of cardiovascular aging in HIV-infected individuals. Dr. Ibáñez joined the Cruchaga Lab for her postdoctoral training in the genetics of neurodegeneration.

Read more...

Dr. Ibáñez’ interests are focused on finding biomarkers useful for the early diagnosis of neurodegeneration, especially Alzheimer’s disease and Parkinson’s disease. The identification of such biomarkers will lead to a better understanding of the pathobiology of the disease, the identification of new therapeutic targets and the possibility of the discovery of an early diagnostic tool.

Read Less...

Message Presenter

Dr. Carlos Cruchaga, Professor of Psychiatry, Washington University of Medicine

Dr. Carlos Cruchaga is the Barbara Burton & Reuben Morriss III Professor of Psychiatry with joint appointments of Genetics and Neurology at Washington University School of Medicine and the Director of the Neurogenomics and Informatics Center.

Dr. Cruchaga is a human genomicist with expertise in multiomics, informatics and neurodegeneration. He completed his PhD in Biochemistry and Molecular Biology in 2005 at the University of Navarra in Spain. During his first postdoc with Dr. Pastor he conducted statistical human genetics studies focused on Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Read more...

He then moved to Dr. Goate’s Lab to complete his training in quantitative human genomics. Dr. Cruchaga established his laboratory at Washington University in 2011 to study the genetic architecture of neurodegenerative diseases. His interests are focused on using human genomic and other -omic data (proteomics, metabolomics and lipidomics) to identify and understand the biological processes that lead to AD, PD, frontotemporal dementia and other neurodegenerative processes. He is the founding director of the NeuroGenomics and Informatics Center at Washington University.

Read Less...

Message Presenter